Carlsmed reported 3Q25 orthopedic sales of $13.1 million, up 98.4% compared to the third quarter of 2024. For the first nine months of the year, the company generated $35.3 million in orthopedic sales, up 99.1% compared to the prior period.
In addition to nearly doubling its quarter-over-quarter sales, Carlsmed increased its surgeon user base by more than 70% year-over-year. The company decreased its aprevo lead times from 20 business days in Q3 2024 to eight days currently.
Finally, the CMS New Technology Add-On Payment (NTAP) went into effect on October 1, 2025, for aprevo cervical procedures which are expected to launch commercially in early 2026.
The company increased its guidance range to $49 million to $50 million, representing growth between 80% and 84%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
3Q25
3Q24
$ Chg
% Chg
Spine
$13.1
$6.6
$6.5
98.4%
Segment
9mo25
9mo24
$ Chg
% Chg
Spine
$35.3
$17.8
$17.6
99.1%
Company Earnings
Amt
% of Sales
Sales
$13.1
Cost of Sales
$3.1
24.1%
Sales and Marketing
$4.4
34%
General and Admin
$9.6
73.5%
R & D
$4.9
37.5%
Other
($0.5)
(3.9%)
Net Earnings
($8.5)
(65.2%)
Carlsmed reported 3Q25 orthopedic sales of $13.1 million, up 98.4% compared to the third quarter of 2024. For the first nine months of the year, the company generated $35.3 million in orthopedic sales, up 99.1% compared to the prior period.
In addition to nearly doubling its quarter-over-quarter sales, Carlsmed increased its surgeon user...
Carlsmed reported 3Q25 orthopedic sales of $13.1 million, up 98.4% compared to the third quarter of 2024. For the first nine months of the year, the company generated $35.3 million in orthopedic sales, up 99.1% compared to the prior period.
In addition to nearly doubling its quarter-over-quarter sales, Carlsmed increased its surgeon user base by more than 70% year-over-year. The company decreased its aprevo lead times from 20 business days in Q3 2024 to eight days currently.
Finally, the CMS New Technology Add-On Payment (NTAP) went into effect on October 1, 2025, for aprevo cervical procedures which are expected to launch commercially in early 2026.
The company increased its guidance range to $49 million to $50 million, representing growth between 80% and 84%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
3Q25
3Q24
$ Chg
% Chg
Spine
$13.1
$6.6
$6.5
98.4%
Segment
9mo25
9mo24
$ Chg
% Chg
Spine
$35.3
$17.8
$17.6
99.1%
Company Earnings
Amt
% of Sales
Sales
$13.1
Cost of Sales
$3.1
24.1%
Sales and Marketing
$4.4
34%
General and Admin
$9.6
73.5%
R & D
$4.9
37.5%
Other
($0.5)
(3.9%)
Net Earnings
($8.5)
(65.2%)
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
